Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Feb 21 2019

• By Brenda Sandburg

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.

Related Content

Pay-For-Delay Deals May Be Smaller After Supreme Court Okays FTC Suits

Jun 24 2013

Impax Defeats FTC Pay-For-Delay Complaint, Helped By Status As Sole Marketer Of Generic Opana ER

May 21 2018

FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Jul 02 2018

Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling

Nov 02 2017

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

Jan 25 2017

Launch Abbreviated: Teva Halts US Generic Sensipar Sales After Patent Deal With Amgen

Jan 03 2019

FTC v. Endo: Does No-Authorized Generic Agreement Meet Supreme Court Pay-For-Delay Test?

Mar 31 2016

Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals

May 29 2015

Patent Settlements Blocking Authorized Generics May Get Supreme Court Review

Apr 05 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Cephalon, Inc.

Endo, Inc.

Allergan plc

Abbott

AbbVie Inc.

Teva Pharmaceutical Industries Ltd.

Allergan plc

GSK plc

Amgen, Inc.

Additional Topics

United States Generic Drugs Policy Legal Issues BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window